Antineoplaston AS2-1 is a mixture of two products of hydrolysis of
Antineoplaston A10 and consists of
sodium salts of
phenylacetylglutamine and
phenylacetic acid in the ratio of 1:4.
Antineoplaston AS2-1 injections were administered to 20 patients diagnosed with 21 types of neoplastic diseases. The patients' diagnoses included:
lung cancer, stage III, 4 cases; colorectal, stage IV, 3; breast, stage IV, 2; breast in remission, 1;
glioblastoma, 3; head and neck, stage IV, 3; uterine cervix, stage IA, 1; chronic myelocytic leukaemia, 2;
lymphocytic lymphoma, stage IV, 1; and
leiomyosarcoma of the uterus, stage IVB, 1.
Antineoplaston AS2-1 was administered every 6 h i.v. through subclavian vein
catheter. The treatment was administered from 38 to 872 days. The highest dosage taken was 160 mg/kg/24 h. The treatment was associated with minimal side-effects, including slight
nausea and
vomiting in one patient, mild
allergic reaction in the form of maculopapular
rash in another patient and moderate elevation of blood pressure in an additional patient. One patient developed febrile reaction and three patients had mild
electrolyte imbalance. Only one patient showed slight decrease of WBC. Desirable side-effects included improved healing of chronic atrophic ulceration. The response to the treatment included 6 complete remissions, 2 partial remissions, 7 cases of stabilization and 6 cases of increasing disease. Three patients are alive, well and free from
cancer 5 years after the beginning of the study. The hypothetical mechanism of action of
Antineoplaston AS2-1 as an
anticancer agent is described.